Celgene pulls EU application for anemia-drug approval

06/2/2008 | Boston Globe (tiered subscription model), The · Reuters

The European Medicines Agency has again declined to recommend approval for Celgene's Revlimid, prompting the company to withdraw its application to market the anemia drug for transfusion-dependent patients with myelodysplastic syndromes. The drugmaker said it will not abandon plans to seek approval for the indication in Europe despite the agency's negative review.

View Full Article in:

Boston Globe (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI